# A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis With Randomized Withdrawal and Retreatment

> **NCT02207244** · PHASE3 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 992 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** Guselkumab 100 mg
- **DRUG:** Placebo for guselkumab
- **DRUG:** Adalimumab
- **DRUG:** Placebo for adalimumab

## Key facts

- **NCT ID:** NCT02207244
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11-03
- **Primary completion:** 2015-10-01
- **Final completion:** 2020-07-01
- **Target enrollment:** 992 (ACTUAL)
- **Last updated:** 2021-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02207244

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02207244, "A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis With Randomized Withdrawal and Retreatment". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02207244. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*